Entero Therapeutics, Inc.
ENTO
$1.94
$0.042.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.40M | 6.98M | 14.72M | 16.22M | 16.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.56M | 7.34M | 15.62M | 18.51M | 20.05M |
| Operating Income | -4.56M | -7.34M | -15.62M | -18.51M | -20.05M |
| Income Before Tax | -4.71M | -7.47M | -15.62M | -18.53M | -20.06M |
| Income Tax Expenses | -- | 4.26M | -10.60M | -10.60M | -10.60M |
| Earnings from Continuing Operations | -15.32 | -22.33 | -15.62 | -7.92 | -9.46 |
| Earnings from Discontinued Operations | -1.76M | -2.56M | -2.44M | -2.00M | -1.32M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.08M | -24.89M | -18.06M | -9.92M | -10.78M |
| EBIT | -4.56M | -7.34M | -15.62M | -18.51M | -20.05M |
| EBITDA | -4.58M | -7.34M | -15.61M | -18.46M | -19.99M |
| EPS Basic | -12.98 | -23.87 | -13.66 | -20.01 | -45.88 |
| Normalized Basic EPS | -0.48 | -3.01 | -12.37 | -23.11 | -39.36 |
| EPS Diluted | -13.13 | -24.01 | -21.91 | -28.26 | -54.13 |
| Normalized Diluted EPS | -0.48 | -3.01 | -3.86 | -14.61 | -30.85 |
| Average Basic Shares Outstanding | 5.84M | 5.02M | 4.01M | 3.13M | 1.74M |
| Average Diluted Shares Outstanding | 5.84M | 5.02M | 8.26M | 7.38M | 5.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |